Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2018-07

    • EZ Cap™ Human PTEN mRNA (ψUTP): High-Fidelity Tumor Suppr...

    2026-02-06

    EZ Cap™ Human PTEN mRNA (ψUTP): High-Fidelity Tumor Suppressor mRNA for PI3K/Akt Pathway Inhibition

    Executive Summary: EZ Cap™ Human PTEN mRNA (ψUTP) is a research-grade, in vitro transcribed mRNA encoding the human PTEN tumor suppressor, supplied at 1 mg/mL in 1 mM sodium citrate (pH 6.4), and optimized with Cap1 structure and pseudouridine modifications for maximal stability and translation in mammalian systems (APExBIO). The Cap1 structure, enzymatically installed with Vaccinia virus capping enzymes and 2'-O-Methyltransferase, provides superior transcriptional efficiency compared to Cap0 variants (Dong et al., 2022). Incorporation of pseudouridine triphosphate (ψUTP) enhances mRNA stability and reduces innate immune activation in vitro and in vivo. PTEN expression from this mRNA enables potent inhibition of the PI3K/Akt pathway, a key axis in cancer cell survival and drug resistance. This reagent is designed for reproducible, immune-evasive gene restoration in cancer research, with strict handling and storage parameters to maintain RNA integrity.

    Biological Rationale

    PTEN is a dual-specificity phosphatase that functions as a critical tumor suppressor by antagonizing PI3K signaling, thereby inhibiting the pro-tumorigenic Akt pathway (Dong et al., 2022). Loss or inactivation of PTEN is frequently observed in a range of malignancies, contributing to uncontrolled cellular proliferation, survival, and resistance to therapies such as trastuzumab in breast cancer (Dong et al., 2022). Restoring PTEN function by exogenous delivery of stabilized, immune-evasive mRNA represents a targeted strategy to suppress the PI3K/Akt pathway and overcome resistance mechanisms. The mRNA format is transient, allowing temporal control and avoiding permanent genomic alteration, which is advantageous in preclinical and translational settings (see related: stability and delivery).

    Mechanism of Action of EZ Cap™ Human PTEN mRNA (ψUTP)

    EZ Cap™ Human PTEN mRNA (ψUTP) is synthesized in vitro, incorporating pseudouridine triphosphate (ψUTP) and a poly(A) tail to enhance RNA stability and translation efficiency while reducing recognition by pattern recognition receptors (PRRs) responsible for innate immune sensing (contrast: immune evasion details). The Cap1 structure, generated by VCE and 2'-O-Methyltransferase, mimics the natural eukaryotic mRNA cap found in mammalian cells, further promoting efficient translation and minimizing immune activation. Upon transfection into mammalian cells using an appropriate transfection reagent, the mRNA is rapidly translated into functional PTEN protein, which dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), antagonizing PI3K activity and repressing Akt-mediated signaling cascades. This results in apoptosis induction, cell cycle arrest, and attenuation of pro-survival signals in cancer cells (Dong et al., 2022).

    Evidence & Benchmarks

    • Systemic delivery of PTEN mRNA via nanoparticles restores PTEN levels and reverses trastuzumab resistance in HER2-positive breast cancer models (Dong et al., 2022).
    • Pseudouridine-modified mRNA exhibits increased stability and reduced innate immune activation compared to unmodified mRNA in mammalian cells (Dong et al., 2022).
    • Cap1-structured mRNA demonstrates higher translation efficiency and lower immunogenicity than Cap0-structured mRNA in vitro and in vivo (Dong et al., 2022).
    • In vitro transcribed PTEN mRNA delivered at ~1 mg/mL supports robust gene expression in cell-based assays targeting the PI3K/Akt pathway (internal: experimental reproducibility).
    • Poly(A) tail and buffer formulation (1 mM sodium citrate, pH 6.4) preserve mRNA integrity during storage at -40°C or below (APExBIO).

    Applications, Limits & Misconceptions

    Applications:

    • Restoration of tumor suppressor function in preclinical cancer models.
    • Investigation of PI3K/Akt pathway inhibition in cell-based and animal studies.
    • Screening for drug resistance mechanisms related to PTEN loss.
    • Immune-evasive gene expression studies requiring minimal innate immune activation.

    This article extends previous analyses by providing a benchmarked workflow and highlighting quantitative stability and translational efficiency data specific to the Cap1/ψUTP formulation.

    Common Pitfalls or Misconceptions

    • Direct Addition to Serum Media: The mRNA should not be directly added to serum-containing media without a transfection reagent, as this leads to rapid degradation (APExBIO).
    • Repeated Freeze-Thaw Cycles: Aliquoting and storage at -40°C or below are critical; repeated freeze-thawing significantly reduces mRNA integrity.
    • RNase Contamination: Use only RNase-free reagents and materials to prevent degradation.
    • Not for Direct In Vivo Use: The reagent is optimized for preclinical research and gene expression studies, not for direct therapeutic administration in humans.
    • Vortexing: Do not vortex the solution, as this can shear the mRNA and reduce activity.

    Workflow Integration & Parameters

    EZ Cap™ Human PTEN mRNA (ψUTP) (SKU R1026) is supplied at a concentration of ~1 mg/mL in 1 mM sodium citrate, pH 6.4, and must be handled on ice. Upon receipt (shipped on dry ice), aliquot immediately to avoid freeze-thaw cycles. Use only RNase-free consumables and work in a dedicated RNA workspace. For cell-based assays, transfect using a validated mRNA transfection reagent; do not add directly to serum-containing media. The mRNA is 1467 nucleotides in length and includes a poly(A) tail for optimal translation. For in vitro applications, titrate the dose based on cell type and endpoint. Store unused aliquots at -40°C or below. Do not vortex. This workflow ensures maximal activity and reproducibility in gene expression and signaling pathway studies (see: scenario-driven deployment).

    Conclusion & Outlook

    EZ Cap™ Human PTEN mRNA (ψUTP) from APExBIO provides a rigorously engineered tool for restoring tumor suppressor activity and dissecting PI3K/Akt pathway dynamics in cancer research. Its advanced Cap1 and pseudouridine modifications maximize translation and minimize immune recognition, outperforming conventional mRNA reagents. Researchers should adhere strictly to recommended handling protocols to preserve reagent integrity. This product supports next-generation studies into tumor suppressor function, drug resistance, and mRNA-based gene expression, with potential translational applications as systemic mRNA delivery strategies mature (Dong et al., 2022).